001     868117
005     20210130004112.0
024 7 _ |a 10.1080/14737175.2020.1704256
|2 doi
024 7 _ |a 1473-7175
|2 ISSN
024 7 _ |a 1744-8360
|2 ISSN
024 7 _ |a 2128/23998
|2 Handle
024 7 _ |a pmid:31829748
|2 pmid
024 7 _ |a WOS:000503631900001
|2 WOS
037 _ _ |a FZJ-2019-06704
082 _ _ |a 610
100 1 _ |a Langen, Karl-Josef
|0 P:(DE-Juel1)131777
|b 0
|e Corresponding author
|u fzj
245 _ _ |a Advantages and limitations of amino acid PET for tracking therapy response in glioma patients
260 _ _ |a Abingdon
|c 2020
|b Taylor & Francis Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1579705540_19971
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Introduction: Today, magnetic resonance imaging (MRI) is the standard method for monitoring patients with brain tumors. The ability of conventional MRI in differentiating neoplastic tissue from nonspecific, treatment-related changes after surgery, radio-, chemo- or immunotherapy, however, remains limited. Therefore, advanced MRI sequences and positron emission tomography (PET) are increasingly being considered to improve decision-making.Areas covered: PET using radiolabeled amino acids has evolved into an important diagnostic tool to overcome some of the shortcomings of conventional MRI. In view of the rapidly developing novel treatment strategies, a reliable statement on the response to therapy is becoming increasingly important. This article gives an overview of the current results of PET with radiolabelled amino acids in therapy monitoring of standard therapy as well as various innovative approaches in the treatment of patients with cerebral gliomas.Expert opinion: Amino acid PET has proven to be helpful in therapy monitoring of gliomas, the costs are low in relation to the costs of therapy and the clinical benefit, and a widespread clinical use is highly desirable.
536 _ _ |a 572 - (Dys-)function and Plasticity (POF3-572)
|0 G:(DE-HGF)POF3-572
|c POF3-572
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Heinzel, Alexander
|0 P:(DE-Juel1)132315
|b 1
|u fzj
700 1 _ |a Lohmann, Philipp
|0 P:(DE-Juel1)145110
|b 2
|u fzj
700 1 _ |a Mottaghy, Felix M.
|0 P:(DE-Juel1)132318
|b 3
|u fzj
700 1 _ |a Galldiks, Norbert
|0 P:(DE-Juel1)143792
|b 4
|u fzj
773 _ _ |a 10.1080/14737175.2020.1704256
|g p. 14737175.2020.1704256
|0 PERI:(DE-600)2090856-8
|n 2
|p 137-146
|t Expert review of neurotherapeutics
|v 20
|y 2020
|x 1744-8360
856 4 _ |y Published on 2019-12-18. Available in OpenAccess from 2020-12-18.
|u https://juser.fz-juelich.de/record/868117/files/Langen_Post%20Print_2019_Expert%20Review%20of%20Neurotherapeutics_Advantages%20and%20limitations%20of%20amino%20acid%20PET%20for%20tracking%20therapy%20response.pdf
856 4 _ |y Published on 2019-12-18. Available in OpenAccess from 2020-12-18.
|x pdfa
|u https://juser.fz-juelich.de/record/868117/files/Langen_Post%20Print_2019_Expert%20Review%20of%20Neurotherapeutics_Advantages%20and%20limitations%20of%20amino%20acid%20PET%20for%20tracking%20therapy%20response.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:868117
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)131777
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)132315
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)145110
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 3
|6 P:(DE-Juel1)132318
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)143792
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-572
|2 G:(DE-HGF)POF3-500
|v (Dys-)function and Plasticity
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a Embargoed OpenAccess
|0 StatID:(DE-HGF)0530
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EXPERT REV NEUROTHER : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
920 1 _ |0 I:(DE-Juel1)INM-4-20090406
|k INM-4
|l Physik der Medizinischen Bildgebung
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a I:(DE-Juel1)INM-4-20090406
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21